« Return to News | Drug Sponsors

Adimab completes series F funding, begins expansion

Wednesday, April 4, 2012 10:32 AM

Adimab, a discovery company of fully human antibodies, has closed its over-subscribed Series F financing and acquired a research facility in Lebanon, N.H., where it plans to set up new headquarters.

The additional funds were raised entirely from existing investors, including Google Ventures, Polaris and SV Life Sciences. “These additional funds enhance our already strong balance sheet, allowing us to pursue several complementary opportunities more aggressively,” said Tillman Gerngross, CEO of Adimab.

With the new funding, Adimab plans to expand its platform to additional applications, such as the development of bi-specific antibodies, antibody-drug conjugates, targeting cell based antigens including GPCRs and ion channels, as well as preclinical manufacturing and mammalian cell line development.

“Our focus has always been on helping our partners develop better therapeutic antibodies,” ” said Errik Anderson, COO of Adimab. “Therefore, as we see attractive opportunities to acquire or develop additional capabilities we want to have excess capital to pursue them. Based on the strength of our current business we were able to raise capital under very attractive terms, which made this an easy decision.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.